Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

NVO TEVA AGN FRX Hotels Chemicals Consumer 
Benchmark  United States  NYSE  10,596   2.712 Index Moved Down -0.03%  


Processing
Processing. Please wait...

Sucampo insider: Ryuji Ueno

       

Ryuji Ueno - Sucampo Insider Profile

Chairman of the Board, CEO, Chief Scientific Officer

Dr. Ryuji Ueno M.D. Ph.D. is no longer Chairman of the Board Chief Executive Officer of Sucampo Pharmaceuticals Inc. effective March 3 2014 and Chief Scientific Officer effective March 31 2014. Dr. Ueno became a director in 1996 is a cofounder of company and was Company chief executive officer since September 2006 and Company chief scientific officer since August 2004. Dr. Ueno also became the chairman of Company board of directors effective June 1 2007. Dr. Ueno served as chairman of Company board of directors from December 2000 to September 2006. He also served as chief operating officer from December 1996 to November 2000 and again from March 2006 to September 2006 and as chief executive officer from December 2000 to September 2003. Dr. Ueno cofounded RTech a related pharmaceutical research development and manufacturing company in Japan in September 1989 and served as its President from 1989 to March 2003. In 2010 Dr. Ueno became President of Omotesenke Domonkai Tobushibu a cultural and educational organization for the Eastern United States
Age: 58  Chairman Since 2014  Ph.D    
301-961-3400  http://www.sucampo.com

Other Appointments

SUCAMPO PHARMACEUAR3AGermany Frankfurt
Chairman
Ryuji Ueno EducationUeno earned his M.D. and a Ph.D. in medicinal chemistry from Keio University in Japan, and earned a Ph.D. in Pharmacology from Osaka University . He conducted postgraduate research at Cold Spring Harbor Lab and Kyoto University Department of Medicinal Chemistry.

Management Efficency

The company has return on total asset (ROA) of 6.47 % which means that it generated profit of $6.47 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 12.69 % meaning that it created $12.69 on every $100 dollars invested by stockholders.
The company currently holds 52.72 M in liabilities with Debt to Equity (D/E) ratio of 0.91 which is about average as compared to similar companies. Sucampo Pharmaceuticals Inc has Current Ratio of 2.61 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. Sucampo Pharmaceuticals Inc [SCMP] is traded on NASDAQ General Markets in USA. It is located in Sucampo Pharmaceuticals, Inc.Bethesda, MD and employs 128 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
 
Showing first 30 of many records found

CHAIRMAN Since

Robert DugganPharmacyclics Inc
2009
Sten ScheibyeNovo Nordisk AS
2006
Anji ReddyDr Reddys Laboratories Ltd
N/A
MS Eng)Dr Reddys Laboratories Ltd
N/A
William FarberLannett Company Inc
2011
Moshe ManyTeva Pharmaceutical Industries
2010
Roger KimmelEndo International plc
2007
Phillip FrostTeva Pharmaceutical Industries
2010
MS BTechDr Reddys Laboratories Ltd
N/A
Christopher PatuskyUnited Therapeutics Corporation
2007
Jesper MScNovo Nordisk AS
N/A
David PyottAllergan Inc
2013
Peter StapleDepoMed Inc
2009
G PrasadDr Reddys Laboratories Ltd
2013
Brenton JDForest Laboratories Inc
N/A
Howard SolomonForest Laboratories Inc
2013
Richard CFAPharmacyclics Inc
N/A
Arthur JDLannett Company Inc
N/A
Dilip ShanghviTaro Pharmaceutical Industries
2013
Pr KrinskyTeva Pharmaceutical Industries
N/A
K ReddyDr Reddys Laboratories Ltd
2011
SCMP
Sucampo Pharmaceuticals Inc
USA Stock
Currency: USD - US Dollar
Traded on NASDAQ General Markets
 

Fix Your Portfolios with Sucampo

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Sucampo Pharmaceuticals Inc to your portfolio

Promote Sucampo and Ryuji Ueno

Follow Sucampo with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker

Sucampo Pharmaceuticals Leadership

James Egan, COO
Barbara Munder, Director, MBA
James JD, COO
Peter Lichtlen, President, Ph.D
Thomas JD, EVP
Anthony Celeste, Director
Gayle Dolecek, Director
Kei Tolliver, Director
Stanley Miele, President
Daniel Getman, Director, Ph.D
, MD, Chairman
Ryuji Ueno, Chairman, Ph.D
Silvia Taylor, President, MBA
Peter MD, VP
Thomas Knapp, President
Sachiko Kuno, Director, Ph.D
William Ashton, Director
Cary Claiborne, CFO, MBA
Andrew Smith, Executive
Cary MBA, CFO
MPH PD, Director
Maureen OConnell, Director
Timothy Maudlin, Director
Peter Greenleaf, CEO, MBA
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Find Alpha
Equity Screener
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and families
Research Equities
Insiders Screener
Find insiders across different sectors to evaluate their impact on performance and growth of their entities
Research Insiders

Stock Performance

Shares Outstanding42.79 M
Number of Shares Shorted1.78 M